Using abatacept to treat lung disease in patients with common variable immunodeficiency.
Official title: Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20
Funded at Cincinnati Childrens Hosp Med Ctr · NIH-10893921 · Data updated 2026-11-12
This study is looking at how well a medication called abatacept can help improve lung health in people with common variable immunodeficiency who have a specific lung condition, and it involves trying the drug for six months to see how it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | September 10, 2021 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $529,803 |
| NIH project number | 5R01FD007267-03 |
| Project ID | NIH-10893921 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with common variable immunodeficiency who are experiencing interstitial lung disease.
✕Less likely to help
Patients without a diagnosis of common variable immunodeficiency or those not experiencing lung disease may not benefit from this research.
What this research studies
This research investigates the use of abatacept, a biologic drug, to treat granulomatous-lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). The study will involve a double-blind trial where participants will receive either abatacept or a placebo for six months, followed by an open-label phase where all participants will receive abatacept for an additional six months. The goal is to evaluate the effectiveness and safety of abatacept in improving lung function and overall health in these patients.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients suffering from GLILD associated with CVID.
How similar studies have gone: Previous small-scale studies have shown promising results for abatacept in treating GLILD, indicating potential for success in this larger trial.
Where this research is happening
-
Cincinnati Childrens Hosp Med Ctr
Cincinnati, United States Active
Researchers
- Principal investigator: Jordan, Michael — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Jordan, Michael
Related research
Other NIH-funded projects on the same topics.
-
Abatacept for lung disease in people with common variable immunodeficiency (GLILD)
This compares abatacept with a placebo to see whether abatacept can improve the lung disease (GLILD) that can occur in people with CVID.
-
Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
-
Obinutuzumab for connective tissue disease–related interstitial lung disease in adults
A study will test whether Obinutuzumab, given with standard treatments, can help adults with CTD-ILD breathe better and have fewer disease-related problems.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
Sustained antibody delivery to durably control HIV-1
A project aims to use gene-delivered antibodies to control HIV-1 for a long time without daily pills.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.